Cargando…
Phase I / II trial of dose adjusted EPOCH chemotherapy with bortezomib combined with integrase inhibitor therapy for HTLV-1 associated T-cell leukemia lymphoma
Autores principales: | Ratner, Lee, Ramos, JC, Noy, Ariela, Barta, Stefan, Parikh, Samir, Phillips, Adrienne, Ambinder, Richard, Rauch, Dan, Harding, John, Baydoun, Hicham, Cheng, Xiaogang, Caruso, Breanna, Jacobson, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578736/ http://dx.doi.org/10.1186/1742-4690-12-S1-P21 |
Ejemplares similares
-
Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma
por: Ratner, L, et al.
Publicado: (2016) -
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin’s Lymphoma (AMC-075)
por: Ramos, Juan C., et al.
Publicado: (2018) -
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in human immunodeficiency virus-associated, B-cell non-Hodgkin lymphoma
por: Sparano, Joseph A., et al.
Publicado: (2020) -
Pooled analysis of AIDS Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin’s lymphoma
por: Barta, Stefan K, et al.
Publicado: (2010) -
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
por: Lakhotia, Rahul, et al.
Publicado: (2023)